Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Are Pediatric House Calls the Future? Exploring Patient Perceptions of Home-Centered Health.

Raju SM, Raju RM, Shumskiy I, Morenz AM, Whitney KM, Vernacchio L, Fleegler EW.

Clin Pediatr (Phila). 2019 Sep;58(10):1049-1055. doi: 10.1177/0009922819859869. Epub 2019 Jun 27. No abstract available.

PMID:
31248269
2.

The complexity of neuroinflammation at single-cell resolution.

Raju RM, Tsai LH.

Nat Rev Neurol. 2019 May;15(5):249-250. doi: 10.1038/s41582-019-0165-5. No abstract available.

PMID:
30858531
3.

An Antibacterial β-Lactone Kills Mycobacterium tuberculosis by Disrupting Mycolic Acid Biosynthesis.

Lehmann J, Cheng TY, Aggarwal A, Park AS, Zeiler E, Raju RM, Akopian T, Kandror O, Sacchettini JC, Moody DB, Rubin EJ, Sieber SA.

Angew Chem Int Ed Engl. 2018 Jan 2;57(1):348-353. doi: 10.1002/anie.201709365. Epub 2017 Dec 5.

4.

Home Visits: Advancing Pediatric Training by Preserving Past Traditions.

Shumskiy I, Raju RM, Tschudy MM.

Pediatrics. 2016 Sep;138(3). pii: e20162015. doi: 10.1542/peds.2016-2015. Epub 2016 Aug 24. Review. No abstract available.

5.

Inflammatory signaling in human tuberculosis granulomas is spatially organized.

Marakalala MJ, Raju RM, Sharma K, Zhang YJ, Eugenin EA, Prideaux B, Daudelin IB, Chen PY, Booty MG, Kim JH, Eum SY, Via LE, Behar SM, Barry CE 3rd, Mann M, Dartois V, Rubin EJ.

Nat Med. 2016 May;22(5):531-8. doi: 10.1038/nm.4073. Epub 2016 Apr 4.

6.

Leveraging Advances in Tuberculosis Diagnosis and Treatment to Address Nontuberculous Mycobacterial Disease.

Raju RM, Raju SM, Zhao Y, Rubin EJ.

Emerg Infect Dis. 2016 Mar;22(3):365-9. doi: 10.3201/eid2203.151643.

7.

Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria.

Moreira W, Ngan GJ, Low JL, Poulsen A, Chia BC, Ang MJ, Yap A, Fulwood J, Lakshmanan U, Lim J, Khoo AY, Flotow H, Hill J, Raju RM, Rubin EJ, Dick T.

mBio. 2015 May 5;6(3):e00253-15. doi: 10.1128/mBio.00253-15.

8.

Post-translational regulation via Clp protease is critical for survival of Mycobacterium tuberculosis.

Raju RM, Jedrychowski MP, Wei JR, Pinkham JT, Park AS, O'Brien K, Rehren G, Schnappinger D, Gygi SP, Rubin EJ.

PLoS Pathog. 2014 Mar 6;10(3):e1003994. doi: 10.1371/journal.ppat.1003994. eCollection 2014 Mar.

9.

Bacterial proteolytic complexes as therapeutic targets.

Raju RM, Goldberg AL, Rubin EJ.

Nat Rev Drug Discov. 2012 Oct;11(10):777-89. doi: 10.1038/nrd3846. Review.

PMID:
23023677
10.

Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection.

Raju RM, Unnikrishnan M, Rubin DH, Krishnamoorthy V, Kandror O, Akopian TN, Goldberg AL, Rubin EJ.

PLoS Pathog. 2012 Feb;8(2):e1002511. doi: 10.1371/journal.ppat.1002511. Epub 2012 Feb 16.

11.

The active ClpP protease from M. tuberculosis is a complex composed of a heptameric ClpP1 and a ClpP2 ring.

Akopian T, Kandror O, Raju RM, Unnikrishnan M, Rubin EJ, Goldberg AL.

EMBO J. 2012 Mar 21;31(6):1529-41. doi: 10.1038/emboj.2012.5. Epub 2012 Jan 27.

12.

MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212.

La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR, Biava M, Raju RM, Porretta GC, Alfonso S, Battilocchio C, Javid B, Sorrentino F, Ioerger TR, Sacchettini JC, Manetti F, Botta M, De Logu A, Rubin EJ, De Rossi E.

Antimicrob Agents Chemother. 2012 Jan;56(1):324-31. doi: 10.1128/AAC.05270-11. Epub 2011 Oct 24.

13.

Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay.

Kavanagh O, Estes MK, Reeck A, Raju RM, Opekun AR, Gilger MA, Graham DY, Atmar RL.

Clin Vaccine Immunol. 2011 Jul;18(7):1187-90. doi: 10.1128/CVI.00039-11. Epub 2011 May 18.

14.

Supravital staining: It's role in detecting early malignancies.

Hedge MC, Kamath PM, Shreedharan S, Dannana NK, Raju RM.

Indian J Otolaryngol Head Neck Surg. 2006 Jan;58(1):31-4. doi: 10.1007/BF02907735.

Supplemental Content

Support Center